Read by QxMD icon Read

Future Oncology

Idoroenyi Amanam, Rohan Gupta, Isa Mambetsariev, Ravi Salgia
Lung cancer remains the leading cause of cancer deaths in the world with 1.69 million deaths in 2015. A total of 85% of lung cancer cases are non-small-cell lung cancers (NSCLCs). Driver mutations associated with anaplastic lymphoma kinase (ALK) have been identified in a variety of malignancies, including NSCLC. An ALK inhibitor (crizotinib, ceritinib and alectinib) is the preferred therapeutic approach to those advanced ALK fusion variant-positive NSCLC patients. Brigatinib, a next-generation ALK inhibitor, shows promising activity in ALK-rearranged NSCLC that have previously received crizotinib with response rates in ALTA ranging from 42-50%, intracranial response 42-67% and median progression-free survival 9...
February 16, 2018: Future Oncology
Christy Kim
Microwave ablation (MWA) is a relatively new thermal modality for minimally invasive procedures compared with radiofrequency ablation. Although MWA and radiofrequency ablation are thermal modalities, their underlying physics and principles greatly differ. Consequently, it is imperative that clinicians be aware of how these differences impact realized ablation volumes to consistently ensure technical success and better patient outcomes. This paper will review the nuances specific to MWA technology (i.e., tissue properties, perfusion/heat sink effect, ablation assessment, imaging accuracy and tissue contraction) that are often overlooked based on familiarity with conventional thermal modalities to guide more accurate assessment of post-treatment MWA volumes...
February 14, 2018: Future Oncology
Umberto Russo, Umberto Maestroni, Roberto Vito Papapietro, Vincenzo Trunfio, Francesco Ziglioli, Stefania Ferretti, Luca Brunese, Gianpaolo Carrafiello, Massimo De Filippo
The number of percutaneous radiofrequency ablation procedures performed for renal tumors is progressively increasing worldwide. Periodic imaging follow-up has the double role to guarantee the treatment efficacy over time and to early detect any possible complication. Tumor size reductions, as well as the appearance of the characteristic 'halo sign', are normal findings that represent good ablative outcomes. However the most reliable factor of ablation efficacy remains the total absence of contrast enhancing zones within the ablated area...
February 14, 2018: Future Oncology
(no author information available yet)
No abstract text is available yet for this article.
February 14, 2018: Future Oncology
Alfonso Reginelli, Alfredo Clemente, Claudia Cardone, Fabrizio Urraro, Andrea Izzo, Erika Martinelli, Teresa Troiani, Fortunato Ciardiello, Luca Brunese, Salvatore Cappabianca
AIM: Regorafenib induces radiological changes in liver metastasis among patients with metastatic colorectal cancer (mCRC). The standard criteria used to evaluate solid tumor response (Response Evaluation Criteria in Solid Tumors) may be limited in assessing response to biologic agents with anti-angiogenic action. PATIENTS & METHODS: A total of 67 hepatic lesions in 32 selected patients were analyzed to evaluate tumor attenuation as measured by Hounsfield unit (HU) and size changes...
February 13, 2018: Future Oncology
Francesca Patella, Giuseppe Franceschelli, Mario Petrillo, Mario Sansone, Roberta Fusco, Filippo Pesapane, Giovanni Pompili, Anna Maria Ierardi, Alberto Maria Saibene, Laura Moneghini, Federico Biglioli, Gianpaolo Carrafiello
AIM: To evaluate dynamic contrast-enhanced (DCE)-MRI and diffusion weighted (DW)-MRI diagnostic value to differentiate Warthin tumors (WT) by pleomorphic adenomas (PA). MATERIALS & METHODS: Seven WT and seven PA were examined. DCE- and  DW-MRI parameters were extracted from volumes of interest; volume of interest-based averages and standard deviations were calculated. Statistical analysis included: linear discriminant analysis, receiver operating characteristic curves, sensitivity and specificity...
February 9, 2018: Future Oncology
Kathleen N Moore, Ignace Vergote, Ana Oaknin, Nicoletta Colombo, Susana Banerjee, Amit Oza, Patricia Pautier, Karim Malek, Michael J Birrer
Mirvetuximab soravtansine, an antibody-drug conjugate that binds with high affinity to folate receptor-α to provide tumor-directed delivery of the potent microtubule-disrupting agent DM4, has emerged as a promising investigational agent for the treatment of ovarian cancer, particularly in the setting of platinum-resistant disease. Here we describe the rationale and design of FORWARD I (NCT02631876), the first randomized, multicenter Phase III study to compare the safety and efficacy of mirvetuximab soravtansine versus investigator's choice of chemotherapy in women with folate receptor-α-positive, platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancer...
February 9, 2018: Future Oncology
Michael Grynberg
Michaël Grynberg is an Obstetrician Gynecologist specialized in reproductive medicine. After 1 year as a visiting fellow in the Department of Reproductive Medicine at Cornell University, he returned to work in France as an Attending Physician in the Division of Reproductive Medicine at the University Hôpital Antoine Béclère, Clamart, France. In 2011, he completed his PhD on the topic of the regulation of follicular growth and anti-Müllerian hormone production. Since 2014, he has been Professor of Reproductive Medicine and the Head of the Department of Reproductive Medicine and Fertility Preservation at the University Hospital Jean Verdier, Bondy, France...
February 9, 2018: Future Oncology
Jeffrey Vacirca, Dennis Caruana, George Calcanes, Michael Mosier, Ralph Boccia, Ali McBride
AIM: This retrospective analysis evaluated chemotherapy-induced nausea and vomiting (CINV)-related hydration needs with palonosetron or granisetron extended-release subcutaneous (GERSC), approved in 2016 for CINV prevention. MATERIALS & METHODS: At a community practice, CINV-related hydration per chemotherapy cycle was determined following highly (HEC) or moderately emetogenic chemotherapy (MEC) and a guideline-recommended antiemetic regimen: neurokinin 1 receptor antagonist, dexamethasone and either palonosetron only, GERSC only, or palonosetron switched to GERSC...
February 9, 2018: Future Oncology
Cláudia Gouvinhas, Ramon Andrade De Mello, Daniela Oliveira, José Manuel Castro-Lopes, Pedro Castelo-Branco, Ricardo Sales Dos Santos, Venceslau Hespanhol, Daniel Humberto Pozza
The global burden of lung cancer has been increasing over the past years, and is still a major threat to public health worldwide, leading to disabilities and premature mortality. Despite multifactorial cause, smoking remains as the major etiological factor, followed by occupational exposure to carcinogens, genetic predisposition and other concomitant diseases. In order to reduce the individual and social burden due to the direct and indirect costs related to the lung cancer treatment, accurate methods of screening are needed...
February 8, 2018: Future Oncology
Scott C Flanders, Janet Kim, Samuel Wilson, Jeffrey Braziunas, Sheldon Greenfield, John Billimek, Stanislav Lechpammer, Daniel W Lin, Lawrence Karsh, David I Quinn, Daniel Shevrin, Neal D Shore, James T Symanowski, David F Penson
AIM: To validate the total illness burden index for prostate cancer (TIBI-CaP) in castration-resistant prostate cancer (CRPC) patients. PATIENTS & METHODS: Baseline comorbidity scores collected using the TIBI-CaP were compared with the baseline patient-reported health-related quality of life using the SF-12v2 and FACT-P questionnaires in 302 patients enrolled in the Treatment Registry for Outcomes in CRPC Patients (TRUMPET). RESULTS: Baseline TIBI-CaP scores were negatively correlated with all baseline SF-12v2 domain/composite (p < 0...
February 8, 2018: Future Oncology
Jiabin Zheng, Renjie Li, Haibo Qiu, Tao Chen, Yongjian Zhou, Changming Huang, Guoxin Li, Zhiwei Zhou, Yong Li
AIM: We aimed to investigate the optimal criteria for classifying higher risk forms of gastric gastrointestinal stromal tumor (gGIST). MATERIALS & METHODS: A total of 246 high-risk gGIST patients were enrolled. Univariate and multivariate analyses were conducted to determine the association between clinicopathological features and overall survival. Appropriate cut-off values were calculated to identify those at higher risk of gGIST. RESULTS: Multivariate and univariate analyses revealed that tumor necrosis and mitotic counts are independent risk factors for overall survival...
February 7, 2018: Future Oncology
Mahesh Seetharam, Kantha R Kolla, Sant P Chawla
Eribulin is a structurally simplified, synthetic macrocyclic ketone analog of halichondrin B, which is a natural, polyether macrolide derived from marine sponges. Eribulin exerts its cytotoxicity by its unique microtubule dynamics inhibitory action. Eribulin was approved in 2010 by the US FDA as a third-line therapy for metastatic breast cancer patients previously treated with an anthracycline and a taxane. In 2016, it was approved for treatment of metastatic liposarcoma for patients who have progressed with anthracycline treatment...
February 7, 2018: Future Oncology
Sheelarani Karunanithi, Liraz Levi
No abstract text is available yet for this article.
February 7, 2018: Future Oncology
Vanessa Benham, Jamie J Bernard
No abstract text is available yet for this article.
February 7, 2018: Future Oncology
Samuel Luke Hill, Andrew Davies
The anti-CD20 monoclonal antibody rituximab (MabThera®/Rituxan®) has been proven to improve outcomes in a range of B-cell malignancies. Initially developed as a formulation for intravenous infusion, administration times for rituximab can be prolonged and associated with infusion-related reactions, prompting a combined clinical development program investigating subcutaneous delivery in combination with recombinant human hyaluronidase. As this program comes to fruition, this article reviews the evidence demonstrating subcutaneous rituximab to have noninferior pharmacokinetics when delivered at a fixed-dose as well as equivalent clinical outcomes in the treatment of follicular lymphoma, chronic lymphocytic leukemia and diffuse large B-cell lymphoma...
February 6, 2018: Future Oncology
Chao Tian, Shijie Zhou, Cheng Yi
AIM: To explore the independent prognostic value of NUP43 in terms of overall survival (OS) and the mechanisms of its dysregulation in breast cancer. PATIENTS & METHODS: Bioinformatic analysis was performed by using data from the cancer genome atlas-breast invasive carcinoma. RESULTS: High NUP43 expression was an independent prognostic factor of poor OS in luminal A subtype (HR: 2.400; 95% CI: 1.070-5.379; p = 0.034) and in HER2+ subtype (HR: 10...
February 6, 2018: Future Oncology
Alessandro Gonfiotti, Domenico Viggiano, Stefano Bongiolatti, Luca Bertolaccini, Piergiorgio Solli, Alessandro Bertani, Luca Voltolini, Roberto Crisci, Andrea Droghetti
Enhanced recovery after surgery (ERAS®) is a strategy that seeks to reduce patients' perioperative stress response, thereby reducing potential complications, decreasing hospital length of stay and enabling patients to return more quickly to their baseline functional status. The concept was introduced in the late 1990s and was first adopted for use with patients undergoing open colorectal surgery. Since that time, the concept of ERAS has spread to multiple surgical specialties. This article explores the key elements for patient care using an ERAS protocol applied to minimally invasive thoracic surgery...
February 5, 2018: Future Oncology
David Sanchez-Lorente, Rudith Guzman, Marc Boada, Nicole Carriel, Angela Guirao, Laureano Molins
Video-assisted thoracoscopic surgery (VATS) has showed benefits in terms of pain, hospital stay and accomplishment of adjuvancy therapy versus open surgery in early stage of non-small-cell lung cancer. Over the last years, the indication of VATS technique has been expanded to advanced lung cancer. In this article, we discuss the definition of VATS and advanced lung cancer, and the safety and feasibility of VATS technique for the resection of advanced tumors.
February 5, 2018: Future Oncology
Corrado Spatola, Carmelo Militello, Alessandra Tocco, Vincenzo Salamone, Raffaele Luigi, Marcello Migliore, Dario Marletta, Alessandra Cannizzaro, Roberta Bevilacqua, Pietro Milone, Stefano Pergolizzi, Giuseppe Privitera
The multimodal approach to malignant pleural mesothelioma is gradually becoming the standard of care for this disease in patients with good performance status. Materials & methods: We report our experience concerning eight cases treated with the use of static step-and-shoot intensity-modulated radiotherapy to the whole pleural cavity, in patients already undergoing surgical and/or antiblastic therapy. Results & conclusion: Results at a median follow-up of 16 months showed a median survival from the initial treatment of 29 months, with lung toxicity of grade II reported only in two patients...
February 5, 2018: Future Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"